Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia Letter uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin

publication date

  • January 2019

Research

keywords

  • Letter

Identity

Digital Object Identifier (DOI)

  • 10.1111/bjh.15791